Mar 3, 2014
Press Statement from Intezyne Technologies
Jun 19, 2013
Intezyne Technologies Expands Its Oncology Pipeline Through Strategic Acquisition of Niiki Pharma
May 15, 2012
Intezyne Adds Chief Business Officer Daniel Devers to Management Team
Jan 25, 2012
Intezyne Scientists Gain Cover Art for the Journal of Polymer Chemistry
Intezyne’s IT-235 is a first-in-class targeted gallium-based small molecule administered as oral tablets once daily.
Intezyne believes the IVECT Method is a unique and remarkably safe platform that has the potential to raise the bar in terms of what patients and oncologists can expect from chemotherapy.